SCHEMBL31682925

SCHEMBL31682925

CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@@H]1O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 7/20 0.62
▸ LGALS8 O00214 2/20 0.62
▸ LGALS4 P56470 2/20 0.62
▸ MAPK1 P28482 2/20 0.61
▸ CD69 Q07108 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ AMY2A P04746 2/20 0.48
▸ CHIA Q9BZP6 1/20 0.48
▸ LGALS1 P09382 1/20 0.47
▸ LGALS7; LGALS7B P47929 1/20 0.47
▸ LGALS9 O00182 1/20 0.46
▸ FGF1 P05230 1/20 0.45
▸ FGF2 P09038 1/20 0.45
▸ VEGFA P15692 1/20 0.45
▸ HPSE Q9Y251 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31682915 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL3229913 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL10488345 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL31682911 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL5514293 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL6820124 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL13479975 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL7720011 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL5518959 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL29866098 0.96 MAPK1 (0.65) LGALS3LGALS8LGALS4MAPK1CD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281590-A1 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED ESCHERICHIA COLI SACCHARIDES AND USES THEREOF PFIZER (US) 2025-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281590-A1 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED ESCHERICHIA COLI SACCHARIDES AND USES THEREOF C5AR1, C3AR1, C5 LGALS3 128/4885LGALS8 55/4885LGALS4 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback